Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (23 quarters reported)
$742M in Q4 2020 → $50M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| PP Praxis Precision Medicines I | 44.2% | Unchanged | 65,933 | $22.1M |
| Alto Neuroscience Inc | 35.3% | Unchanged | 667,778 | $17.6M |
| Lenz Therapeutics Inc | 11.6% | Unchanged | 1,017,751 | $5.78M |
| Korro Bio Inc | 7.3% | Unchanged | 276,831 | $3.65M |
| Caribou Biosciences Inc | 1.7% | Unchanged | 474,067 | $834K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
No position changes this quarter.
quarter ended March 31, 2026 · filed May 15, 2026
No position changes this quarter.
quarter ended December 31, 2025 · filed February 17, 2026
No position changes this quarter.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Turnstone Biologics Corp | Exited | −549,980 | −$197K | — |
quarter ended June 30, 2025 · filed August 14, 2025
No position changes this quarter.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Omega Therapeutics Inc | Exited | −352,941 | −$263K | — |
quarter ended December 31, 2024 · filed February 14, 2025
No position changes this quarter.
quarter ended September 30, 2024 · filed November 14, 2024
No position changes this quarter.
Loading...
